Core Insights - The company reported a stable overall performance for the fiscal year ending December 31, 2024, with a slight increase in revenue and profit [1][2] - The business structure continues to optimize, focusing on a combination of finance, comprehensive medical services, specialized medical care, and health technology [1] Financial Performance - Total revenue reached RMB 13.663 billion, a year-on-year increase of 0.1%, with the healthcare segment generating RMB 8.488 billion, up 8.4% [1] - Net profit amounted to RMB 2.258 billion, reflecting a 2.7% increase, with the healthcare segment contributing RMB 522 million, a growth of 15.0% [1] - The return on assets (ROA) was 2.71%, and the return on equity (ROE) stood at 12.37%, indicating stable financial health [1] Financial Services - Financial services revenue totaled RMB 5.227 billion, a decline of 11.1%, while net profit from this segment was RMB 1.748 billion, a slight increase of 0.2% [2] - The company maintained strong asset quality, with net interest-earning assets reaching RMB 71.277 billion, a growth of 5.8% from the beginning of the year [2] - The non-performing asset ratio was 0.99%, and the 30-day overdue rate was 0.97%, with a provision coverage ratio of 301.86%, enhancing risk resilience [2] Strategic Initiatives - The company aims to innovate and transform its financial services while supporting the real economy and its core business [2] - Future plans include transitioning towards four key areas: healthcare, equipment manufacturing, chemical pharmaceuticals, and innovative businesses [2] - The company is developing a new model for medical equipment that combines financing leasing with full lifecycle management, and is also focusing on the development of elderly care finance and digital finance [2]
环球医疗公布2024年度业绩：整体经营稳中向好 业务结构持续优化